Role of prokineticins and T-reg cells in obesity-associated metabolic oxidative dysregulation in NAFLD
We investigate the role of prokineticin, T-reg cells, and oxidative metabolism in the progression of obesity-related NASH to HCC. Our findings on a cohort of 250 patients, including Obese NAFLD and Non-Obese NAFLD, reveal significant insights. In Obese NAFLD, PK-1 mRNA expression was reduced by 2.4-...
Saved in:
| Published in: | Scientific reports Vol. 15; no. 1; pp. 29470 - 14 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
12.08.2025
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| ISSN: | 2045-2322, 2045-2322 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | We investigate the role of prokineticin, T-reg cells, and oxidative metabolism in the progression of obesity-related NASH to HCC. Our findings on a cohort of 250 patients, including Obese NAFLD and Non-Obese NAFLD, reveal significant insights. In Obese NAFLD,
PK-1
mRNA expression was reduced by 2.4-fold (
p
< 0.01) compared to Non-Obese NAFLD, while
PK-2
was upregulated by 1.4-fold (
p
< 0.005), and
FABP-5
increased by 1.4-fold (
p
< 0.005) compared to T2DM.
IL-10
mRNA expression was 2.4-fold higher (
p
< 0.005) in MetS verses to Non-Obese NAFLD.
Nrf-2
expression was elevated by 1.13-fold in Non-Obese NAFLD compared to Obese NAFLD (
p
< 0.05). Flow cytometric analysis of T-reg cells was three times lower in Obese NAFLD compared to MetS (
p
< 0.005), with a notable reduction in CD8
+
cells and an increase in CD4
+
cells. Correlation analysis in Obese NAFLD revealed strong positive correlations between IL-10 and T-reg (
r
= 1), CD4
+
(
r
= 0.99), and CD8
+
cells (
r
= 0.99).
PK-1
expression correlated with CD8
+
cells (
r
= 0.52), while
PK-2
negatively correlated with C-type lectin (
r
=-0.49).
FABP-5
exhibited significant positive correlations with
PK-1
(
r
= 0.54) and
IL-10
(
r
= 0.63). We highlight the interplay between prokineticins, immune modulation, and metabolic oxidative factors to offer potential therapeutic targets to prevent progression to HCC, instilling hope for the future of NASH treatment. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 2045-2322 2045-2322 |
| DOI: | 10.1038/s41598-025-97969-2 |